《运动员心脏猝死风险》

  • 来源专题:心血管疾病防治
  • 编译者: 张燕舞
  • 发布时间:2018-05-22
  • 虽然心脏性猝死(SCD)是运动员死亡的主要医疗原因,但其确切发病率仍不清楚。 到目前为止,最好的估计已经表明,在50,000个运动员年中约有1个发生。 在一项使用加拿大数据库2009年至2014年的数据记录的一项新研究中,该数据库记录了加拿大安大略省所有医院外突发心脏骤停(SCA),运动员SCA的总体速率为每10万运动员年为0.76。 44%的患者在SCA后仍然出院,SCD总发生率为每100,000运动员年0.42。 这些数据表明,运动员SCD的发生率是以前估计的四分之一,并提出了关于预参加筛查的作用的问题。

    BACKGROUND The incidence of sudden cardiac arrest during participation in sports activities remains unknown. Preparticipation screening programs aimed at preventing sudden cardiac arrest during sports activities are thought to be able to identify at-risk athletes; however, the efficacy of these programs remains controversial. We sought to identify all sudden cardiac arrests that occurred during participation in sports activities within a specific region of Canada and to determine their causes.

    METHODS In this retrospective study, we used the Rescu Epistry cardiac arrest database (which contains records of every cardiac arrest attended by paramedics in the network region) to identify all out-of-hospital cardiac arrests that occurred from 2009 through 2014 in persons 12 to 45 years of age during participation in a sport. Cases were adjudicated as sudden cardiac arrest (i.e., having a cardiac cause) or as an event resulting from a noncardiac cause, on the basis of records from multiple sources, including ambulance call reports, autopsy reports, in-hospital data, and records of direct interviews with patients or family members.

    RESULTS Over the course of 18.5 million person-years of observation, 74 sudden cardiac arrests occurred during participation in a sport; of these, 16 occurred during competitive sports and 58 occurred during noncompetitive sports. The incidence of sudden cardiac arrest during competitive sports was 0.76 cases per 100,000 athlete-years, with 43.8% of the athletes surviving until they were discharged from the hospital. Among the competitive athletes, two deaths were attributed to hypertrophic cardiomyopathy and none to arrhythmogenic right ventricular cardiomyopathy. Three cases of sudden cardiac arrest that occurred during participation in competitive sports were determined to have been potentially identifiable if the athletes had undergone preparticipation screening.

    CONCLUSIONS In our study involving persons who had out-of-hospital cardiac arrest, the incidence of sudden cardiac arrest during participation in competitive sports was 0.76 cases per 100,000 athlete-years. The occurrence of sudden cardiac arrest due to structural heart disease was uncommon during participation in competitive sports. (Funded by the National Heart, Lung, and Blood Institute and others.).

相关报告
  • 《营养和脂质调节:对心脏代谢风险因素的影响》

    • 来源专题:食物与营养
    • 编译者:lixiaoman
    • 发布时间:2017-06-26
    • 前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)是参与调节LDL的受体表达和载脂蛋白脂蛋白胆固醇代谢的丝氨酸蛋白酶。肝脏PCSK9蛋白的表达、活性及分泌已显示影响胆固醇体内平衡。肝脏PSCK9蛋白的上调导致LDLR降解的增加,脂蛋白的摄取减少,从而导致这些脂蛋白的血浆浓度升高。因此,PCSK9已经成为降脂疗法的新靶点。 本研究概述了当前关于PCSK9的代谢和膳食调节对胆固醇的影响,以及apoB脂蛋白代谢和心血管疾病(CVD)风险的相关研究成果。
  • 《沙格列汀和阿格列汀可能会增加心脏衰竭的风险》

    • 来源专题:重大新药创制—内分泌代谢
    • 编译者:李永洁2
    • 发布时间:2016-05-13
    • FDA安全审查发现2型糖尿病治疗药物包括沙格列汀和阿格列汀可能会增加心脏衰竭的风险,特别是谁已经有心脏或肾脏疾病的患者。心脏衰竭可导致心脏不能够泵出足够的血液以满足身体的需要。FDA增加新的警告至药品说明中。沙格列汀和阿格列汀是类二肽基肽-4(DPP-4)抑制剂的药物,2型糖尿病患者除了控制饮食和锻炼外,可以使用此类药物来辅助降低血糖。 这项安全警告是基于两项大型的临床试验。接受含沙格列汀和阿格列汀药物治疗的患者的因心脏衰竭的住院率高于安慰剂组的患者。在沙格列汀试验中,接受沙格列汀药物的患者的心脏衰竭住院率为3.5%;安慰剂的患者的心脏衰竭住院率为2.8%。在阿格列汀试验中,接受沙格列汀药物的患者心脏衰竭住院率为3.9%;安慰剂的患者的心脏衰竭住院率为3.3%。 因此,FDA增加了新的警告和注意事项,包含沙格列汀或阿格列汀的药物需在说明书中告知患者有潜在的增加心脏衰竭风险的可能。